Keyword: European Commission

After a tough year in the competitive MS field, Sanofi’s Lemtrada could hardly afford another setback. But that’s exactly what it got.

The EU approval is conditional on selling off a Shire experimental IBD drug, which Takeda said could attract "a number of potential buyers."

Amid reports that it will sell Shire's Xiidra and Natpara, Takeda said it may sell SHP647, a phase 3 bowel drug that would overlap its own Entyvio.

The entry of a fifth biosimilar rival to Humira in Europe could feed fears of a bigger-than-predicted impact on AbbVie.

The Wasdell Group will invest a half-million pounds in a laboratory project that will support its move into sterile manufacturing this year.

Here is some other vaccine news of note for the week.

Vertex has cancelled plans to test an investigational triple combo at several sites in France.

With time running short, EU members have been asked to set aside parochial interests in their pick for a new city to host the EMA.

EU drugmakers are warning of drug supply chaos if the U.K. and European Commission can’t strike a specific deal in advance of the Brexit deadline.

A Danish medicines repackager has again had its manufacturing certificate yanked by regulators just months after it said it had resolved its problems.